These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526 [Abstract] [Full Text] [Related]
5. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Lancet; 2011 Apr 30; 377(9776):1506-13. PubMed ID: 21529928 [Abstract] [Full Text] [Related]
6. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. Lapham S, Forman R, Alexander M, Illeperuma A, Bohn MJ. J Subst Abuse Treat; 2009 Jan 30; 36(1):1-6. PubMed ID: 18775624 [Abstract] [Full Text] [Related]
9. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Alcohol Clin Exp Res; 2009 Feb 30; 33(2):350-6. PubMed ID: 19053979 [Abstract] [Full Text] [Related]
10. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. Collins SE, Duncan MH, Saxon AJ, Taylor EM, Mayberry N, Merrill JO, Hoffmann GE, Clifasefi SL, Ries RK. Lancet Psychiatry; 2021 Apr 30; 8(4):287-300. PubMed ID: 33713622 [Abstract] [Full Text] [Related]
17. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM. Neuroimage; 2013 Sep 30; 78():176-85. PubMed ID: 23571420 [Abstract] [Full Text] [Related]
18. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, Stevens D, Gourevitch MN. J Subst Abuse Treat; 2012 Dec 30; 43(4):458-62. PubMed ID: 22985676 [Abstract] [Full Text] [Related]
19. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Kermack A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD. Contemp Clin Trials; 2019 Jun 30; 81():102-109. PubMed ID: 30986535 [Abstract] [Full Text] [Related]
20. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. Finigan MW, Perkins T, Zold-Kilbourn P, Parks J, Stringer M. J Subst Abuse Treat; 2011 Oct 30; 41(3):288-93. PubMed ID: 21696912 [Abstract] [Full Text] [Related] Page: [Next] [New Search]